Hypertension artérielle pulmonaire et valvulopathies induites par les fenfluramines? Hypothèses ou certitudes? Mythe ou réalité?
Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Cited by 1 publication
References 12 publications
The review by Fishman 1 seems to bring simple answers to a rather complex problem that deserves a more exhaustive analysis. This article establishes a link between an aminorex epidemic of pulmonary hypertension between 1965 and 1972 and the recent fenfluramine affair. By deductive reasoning, the author suggests that all of the complications attributed to fen-phen or fenfluramine alone (ie, pulmonary hypertension and cardiac valvular abnormalities) might simply be explained from a pathogenetic point of view within the framework of dietary pulmonary hypertension. The weakness of this argument must be underlined, because it completely ignores the epidemiological dimensions of the fenfluramine affair.Fenfluramine was launched in France in 1963, 2 years before aminorex was introduced in Switzerland, Austria, and Germany. 2 A few cases of pulmonary hypertension associated with fenfluramine curiously appeared in the European literature in 1981, although the drug had been prescribed for Ͼ500 000 patients. Between 1963 and 1996, fenfluramine was prescribed mainly in Europe in Ͼ50 million patients, 2 and the prevalence of pulmonary hypertension associated with fenfluramine was estimated at Ϸ2 cases per million treated patients. International Primary Pulmonary Hypertension Study (IPPHS) was a case-control study, 3 and its results, which are hypothetical, were not confirmed by other studies or approaches. In science as in medicine, the results of only 1 study are largely insufficient to firmly establish facts or causality. This is an inescapable scientific rule that is more important than the biological credibility of any hypothesis or theory. Thus, there was no fenfluramine epidemic of pulmonary hypertension that could be foretold by a previous aminorex epidemic of pulmonary hypertension. 1On the other side of the Atlantic Ocean, 16 months after the launch of dexfenfluramine (Redux) in the United States, Connolly et al's article 4 resulted in the foretold epidemic of valvular abnormalities. In fact, 5 cases of anatomically documented carcinoid-like valvular heart diseases occurred 4 out of the Ͼ18 million prescriptions for fen-phen in 1996. 1 The other cases of nonspecific valvular abnormalities were documented mainly by echocardiography, with a prevalence that varied between 7% and 32%. 5 This is for the foretold epidemic of anorexigenic-induced valvular heart disease in the United States. 1These basic epidemiological facts cannot be ignored when considering some speculations about the pathogenetic mechanisms of the fenfluramine affair. Other, more plausible mechanisms for its cause should be explored. These include the following: (1) the limitations of methods such as case-control studies and echocardiography in the field of pharmacoepidemiology and the lack of a gold standard for the rigorous evaluation of such methods; (2) the reproducibility of echocardiographic results in the multicenter evaluation of valvular regurgitation, particularly in obese patients; and (3) the role of biases, artifacts, and the extreme medial...
The review by Fishman 1 seems to bring simple answers to a rather complex problem that deserves a more exhaustive analysis. This article establishes a link between an aminorex epidemic of pulmonary hypertension between 1965 and 1972 and the recent fenfluramine affair. By deductive reasoning, the author suggests that all of the complications attributed to fen-phen or fenfluramine alone (ie, pulmonary hypertension and cardiac valvular abnormalities) might simply be explained from a pathogenetic point of view within the framework of dietary pulmonary hypertension. The weakness of this argument must be underlined, because it completely ignores the epidemiological dimensions of the fenfluramine affair.Fenfluramine was launched in France in 1963, 2 years before aminorex was introduced in Switzerland, Austria, and Germany. 2 A few cases of pulmonary hypertension associated with fenfluramine curiously appeared in the European literature in 1981, although the drug had been prescribed for Ͼ500 000 patients. Between 1963 and 1996, fenfluramine was prescribed mainly in Europe in Ͼ50 million patients, 2 and the prevalence of pulmonary hypertension associated with fenfluramine was estimated at Ϸ2 cases per million treated patients. International Primary Pulmonary Hypertension Study (IPPHS) was a case-control study, 3 and its results, which are hypothetical, were not confirmed by other studies or approaches. In science as in medicine, the results of only 1 study are largely insufficient to firmly establish facts or causality. This is an inescapable scientific rule that is more important than the biological credibility of any hypothesis or theory. Thus, there was no fenfluramine epidemic of pulmonary hypertension that could be foretold by a previous aminorex epidemic of pulmonary hypertension. 1On the other side of the Atlantic Ocean, 16 months after the launch of dexfenfluramine (Redux) in the United States, Connolly et al's article 4 resulted in the foretold epidemic of valvular abnormalities. In fact, 5 cases of anatomically documented carcinoid-like valvular heart diseases occurred 4 out of the Ͼ18 million prescriptions for fen-phen in 1996. 1 The other cases of nonspecific valvular abnormalities were documented mainly by echocardiography, with a prevalence that varied between 7% and 32%. 5 This is for the foretold epidemic of anorexigenic-induced valvular heart disease in the United States. 1These basic epidemiological facts cannot be ignored when considering some speculations about the pathogenetic mechanisms of the fenfluramine affair. Other, more plausible mechanisms for its cause should be explored. These include the following: (1) the limitations of methods such as case-control studies and echocardiography in the field of pharmacoepidemiology and the lack of a gold standard for the rigorous evaluation of such methods; (2) the reproducibility of echocardiographic results in the multicenter evaluation of valvular regurgitation, particularly in obese patients; and (3) the role of biases, artifacts, and the extreme medial...
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
Contact Info
customersupport@researchsolutions.com
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Product
Resources
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.
